Annovis Bio Files 8-K on Financials
Ticker: ANVS · Form: 8-K · Filed: May 13, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | May 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
Annovis Bio dropped an 8-K on May 13th detailing their financial condition. Check it for the latest numbers.
AI Summary
Annovis Bio, Inc. filed an 8-K on May 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the report period ending on May 13, 2024. The company, previously known as QR Pharma, Inc., is incorporated in Delaware and headquartered in Malvern, PA.
Why It Matters
This filing provides an update on Annovis Bio's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not contain new material events or significant risk disclosures.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former Company Name
- May 13, 2024 (date) — Report Date
- Malvern, PA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Annovis Bio, Inc.?
The primary purpose of this 8-K filing is to report on Annovis Bio, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
On what date was this 8-K report filed and as of what date is it effective?
This 8-K report was filed on May 13, 2024, and the date as of which the report is filed and the date of change are both May 13, 2024.
What is the principal executive office address for Annovis Bio, Inc.?
The principal executive office address for Annovis Bio, Inc. is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What was Annovis Bio, Inc.'s former company name?
Annovis Bio, Inc.'s former company name was QR Pharma, Inc.
What is the Standard Industrial Classification (SIC) code for Annovis Bio, Inc.?
The Standard Industrial Classification (SIC) code for Annovis Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-05-13 16:05:46
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2414281d1_8k.htm (8-K) — 25KB
- tm2414281d1_ex99-1.htm (EX-99.1) — 22KB
- 0001104659-24-060518.txt ( ) — 224KB
- anvs-20240513.xsd (EX-101.SCH) — 3KB
- anvs-20240513_lab.xml (EX-101.LAB) — 33KB
- anvs-20240513_pre.xml (EX-101.PRE) — 22KB
- tm2414281d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On May 13, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits Exhibit No. Description 99.1 Press Release Dated May 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: May 13, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer